Compare Linde PLC (LIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Merck & Co., Inc. — how do they compare? Linde PLC trades at $509.24 (market cap $236.74B), while Merck & Co., Inc. trades at $126.19 (market cap $307.25B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| LIN | MRK | |
|---|---|---|
Market Cap | $236.74B | $307.25B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $129.52 |
52-Week Low | $389.38 | $77.60 |
Enterprise Value | $259.10B | $350.66B |
Dividend Yield | 1.25% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $513.07, down 1.47% today, with strong fundamentals including 20.44% net income margin and consistent earnings beats. Technical indicators show a bearish trend with support at $509 and resistance at $520. The company maintains robust cash flow from operations of $10.35B and has raised dividends, reflecting financial health.
Outlook remains positive with 89% analyst buy ratings and a $564.80 price target, though valuation ratios are elevated. Risks include rising debt-to-asset ratio (31.63% in 2025) and potential macroeconomic pressures. The stock offers growth potential but requires monitoring of leverage and market conditions.
Merck (MRK) trades at $124.30, down 2.51% over the past day, amid a generally bullish technical setup with moving averages signaling strength. The company reported solid earnings beats in recent quarters, including Q1 2026, with revenue reaching $65.01B in 2025 and net income of $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Analyst sentiment remains strongly positive, with a consensus price target of $137.30 and 68% buy ratings.
The outlook for MRK is favorable, supported by robust profitability margins, strategic acquisitions, and strong institutional interest. Key risks include integration challenges from recent M&A, patent expirations, and regulatory pressures. The stock's current valuation at a P/E of 35.04 may limit near-term upside, but long-term growth drivers in pharmaceuticals provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
